113 related articles for article (PubMed ID: 38445718)
1. Empowering SARS-CoV-2 variant neutralization with a bifunctional antibody engineered with tandem heptad repeat 2 peptides.
Kim JW; Lee JH; Kim HJ; Heo K; Lee Y; Jang HJ; Lee HY; Park JW; Cho YB; Shin HG; Yang HR; Lee HE; Song JY; Lee S
J Med Virol; 2024 Mar; 96(3):e29506. PubMed ID: 38445718
[TBL] [Abstract][Full Text] [Related]
2. Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants.
Kim JW; Heo K; Kim HJ; Yoo Y; Cho HS; Jang HJ; Lee HY; Ko IY; Woo JR; Cho YB; Lee JH; Yang HR; Shin HG; Choi HL; Hwang K; Kim S; Kim H; Chun K; Lee S
Antiviral Res; 2023 Apr; 212():105576. PubMed ID: 36870394
[TBL] [Abstract][Full Text] [Related]
3. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
[TBL] [Abstract][Full Text] [Related]
4. A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variants.
Kim JW; Kim HJ; Heo K; Lee Y; Jang HJ; Lee HY; Park JW; Cho YB; Lee JH; Shin HG; Yang HR; Choi HL; Shim HB; Lee S
Front Immunol; 2023; 14():1271508. PubMed ID: 37822941
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants.
Ko SH; Chen WY; Su SC; Lin HT; Ke FY; Liang KH; Hsu FF; Kumari M; Fu CY; Wu HC
J Biomed Sci; 2022 Dec; 29(1):108. PubMed ID: 36550570
[TBL] [Abstract][Full Text] [Related]
6. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
[TBL] [Abstract][Full Text] [Related]
7. A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern.
Xing L; Xu X; Xu W; Liu Z; Shen X; Zhou J; Xu L; Pu J; Yang C; Huang Y; Lu L; Jiang S; Liu S
Viruses; 2022 Mar; 14(3):. PubMed ID: 35337003
[TBL] [Abstract][Full Text] [Related]
8. An Engineered IgG-VHH Bispecific Antibody against SARS-CoV-2 and Its Variants.
Chi H; Wang L; Liu C; Cheng X; Zheng H; Lv L; Tan Y; Zhang N; Zhao S; Wu M; Luo D; Qiu H; Feng R; Fu W; Zhang J; Xiong X; Zhang Y; Zu S; Chen Q; Ye Q; Yan X; Hu Y; Zhang Z; Yan R; Yin J; Lei P; Wang W; Lang G; Shao J; Deng Y; Wang X; Qin C
Small Methods; 2022 Dec; 6(12):e2200932. PubMed ID: 36300882
[TBL] [Abstract][Full Text] [Related]
9. IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern.
Chang MR; Tomasovic L; Kuzmina NA; Ronk AJ; Byrne PO; Johnson R; Storm N; Olmedillas E; Hou YJ; Schäfer A; Leist SR; Tse LV; Ke H; Coherd C; Nguyen K; Kamkaew M; Honko A; Zhu Q; Alter G; Saphire EO; McLellan JS; Griffiths A; Baric RS; Bukreyev A; Marasco WA
Nat Commun; 2022 Oct; 13(1):5814. PubMed ID: 36192374
[TBL] [Abstract][Full Text] [Related]
10. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
Elife; 2022 Aug; 11():. PubMed ID: 36004719
[TBL] [Abstract][Full Text] [Related]
11. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
[TBL] [Abstract][Full Text] [Related]
12. Novel Affibody Molecules Specifically Bind to SARS-CoV-2 Spike Protein and Efficiently Neutralize Delta and Omicron Variants.
Du W; Jiang P; Li Q; Wen H; Zheng M; Zhang J; Guo Y; Yang J; Feng W; Ye S; Kamara S; Jiang P; Chen J; Li W; Zhu S; Zhang L
Microbiol Spectr; 2023 Feb; 11(1):e0356222. PubMed ID: 36511681
[TBL] [Abstract][Full Text] [Related]
13. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
14. Distinct in vitro and in vivo neutralization profiles of monoclonal antibodies elicited by the receptor binding domain of the ancestral SARS-CoV-2.
Kwon HJ; Zhang J; Kosikova M; Tang W; Ortega-Rodriguez U; Peng H; Meseda CA; Pedro CL; Schmeisser F; Lu J; Kang I; Zhou B; Davis CT; Wentworth DE; Chen WH; Shriver MC; Barnes RS; Pasetti MF; Weir JP; Chen B; Xie H
J Med Virol; 2023 Mar; 95(3):e28673. PubMed ID: 36916782
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
[TBL] [Abstract][Full Text] [Related]
16. Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses.
Lim HT; Kok BH; Lim CP; Abdul Majeed AB; Leow CY; Leow CH
Biomed Eng Adv; 2022 Dec; 4():100054. PubMed ID: 36158162
[TBL] [Abstract][Full Text] [Related]
17. An engineered bispecific human monoclonal antibody against SARS-CoV-2.
Li Z; Li S; Zhang G; Peng W; Chang Z; Zhang X; Fan Z; Chai Y; Wang F; Zhao X; Li D; Zhang R; He Z; Zou W; Xu K; Lei W; Liu P; Hao J; Zhang J; Sun L; Wu G; Tan S; Gao GF; Gao F; Wu Y
Nat Immunol; 2022 Mar; 23(3):423-430. PubMed ID: 35228696
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis.
Tao K; Tzou PL; Kosakovsky Pond SL; Ioannidis JPA; Shafer RW
Microbiol Spectr; 2022 Aug; 10(4):e0092622. PubMed ID: 35700134
[TBL] [Abstract][Full Text] [Related]
19. The variable conversion of neutralizing anti-SARS-CoV-2 single-chain antibodies to IgG provides insight into RBD epitope accessibility.
Chang MR; Ke H; Losada Miguéns L; Coherd C; Nguyen K; Kamkaew M; Johnson R; Storm N; Honko A; Zhu Q; Griffiths A; Marasco WA
Protein Eng Des Sel; 2023 Jan; 36():. PubMed ID: 37561410
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
